China

Aspen China is set to become a significant contributor to the Group performance with a product range comprising the recently acquired Thrombosis and Anaesthetic Brands as well as some smaller global brands.

Contribution to Group revenue

Revenue contribution - by therapeutic category

China made up 37% of the total Asian pharmaceutical sector with an estimated value of USD80 billion as at 30 December 2016.

Over the same period, the China pharmaceutical sector grew 7,9% in local currency, mostly driven by the 8,4% growth in prescription medication usage in hospitals.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2017: nil)

Number of product recalls:

Nil

(2017: nil)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in: